Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies
2019; BMJ; Volume: 78; Issue: 6 Linguagem: Inglês
10.1136/annrheumdis-2018-214690
ISSN1468-2060
AutoresFabricio Espinosa‐Ortega, Marie Holmqvist, Helene Alexanderson, Helena Storfors, Tsuneyo Mimori, Ingrid E. Lundberg, Johan Rönnelid,
Tópico(s)Immunodeficiency and Autoimmune Disorders
ResumoMore than 15 autoantibodies have been identified in patients with idiopathic inflammatory myopathies (IIM). Most of them are specific to patients with IIM and therefore called myositis-specific autoantibodies (MSA).1 There is no standardised approach of MSA testing to be used in clinical settings. Immunoprecipitation (IP) of RNA and/or proteins in cellular lysates has traditionally been considered the golden standard for most autoantibodies but does not differentiate between antibodies targeting proteins with the same molecular weight and is not routinely available. Line blot assays (LB) represent a faster and semi-quantitative option to detect autoantibodies.2 3 Our aim was to compare a LB version with 16 specificities and an IP-based algorithm, as well as to describe clinical associations to autoantibody specificities in a cohort of patients classified as IIM. The first available sera collected between 2013 and 2017, from 110 patients classified as having IIM4 followed at the rheumatology clinic at Karolinska University Hospital (Stockholm, Sweden) and sera from 60 healthy controls were included. We used a commercial LB assay (Euroline Myositis …
Referência(s)